Jason Aryeh
CIK 1376960 · last filed 2026-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$34.75M
Companies
11
Total Filings
170
Lifetime Open-Market Net
-$33.00M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LFCR | Director | 69,967 | $5.64 | $394.6K | $0 | 3 | 2026-06-05 |
| OBIO | Director | 118,118 | $4.10 | $484.3K | $39.9K | 12 | 2026-05-20 |
| LGND | Director | 76,348 | $255.54 | $19.51M | -$30.56M | 66 | 2025-12-08 |
| Anebulo Pharmaceuticals, Inc. (ANEB) Delisted | Director | — | $0.36 | — | $0 | 3 | 2025-04-07 |
| MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | 10%+ Owner | 3,802 | $15.13 | $57.5K | $21.5K | 2 | 2019-07-18 |
| Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Director | 15,000 | — | — | $1.17M | 4 | 2017-05-24 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | 369,924 | — | — | $3.2K | 2 | 2017-05-17 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | — | — | — | $0 | 1 | 2017-01-10 |
| QLTI | Director | 535,478 | $26.82 | $14.36M | $1.05M | 18 | 2016-06-21 |
| Myrexis, Inc. (MYRX) Delisted | Director | 9,900 | — | — | $1.15M | 19 | 2012-06-20 |
| Vaxart, Inc. (NABI) Delisted | Director | 131,783 | — | — | -$5.87M | 39 | 2011-05-27 |
Recent Filings · Page 5 of 17
170 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-08-17 | LGND | Sell (S) | −27,942 | -$6.76M | EDGAR |
| 2018-07-03 | LGND | Grant (A) | — | $0 | EDGAR |
| 2018-06-21 | LGND | Grant (A) | +493 | $0 | EDGAR |
| 2018-03-09 | LGND | Sell (S) | −7,500 | -$1.32M | EDGAR |
| 2018-02-27 | LGND | Mixed | −4,417 | -$529.6K | EDGAR |
| 2017-11-20 | LGND | Sell (S) | −24,400 | -$3.42M | EDGAR |
| 2017-08-25 | LGND | Sell (S) | −2,000 | -$256.0K | EDGAR |
| 2017-05-26 | LGND | Grant (A) | +666 | $0 | EDGAR |
| 2017-05-24 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Sell (S) | −388,685 | -$558.8K | EDGAR |
| 2017-05-17 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Buy (P) | +361 | $3.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.